For the best experience, please view this page on a desktop device
This information is provided in response to your request. Resources may contain information and data outside of the US FDA-approved Prescribing Information. In providing this data, Alnylam Pharmaceuticals, Inc. is not making any representations as to its clinical relevance. For information about the approved conditions of use of vutrisiran, please consult the FDA-approved Prescribing Information.
Use this interactive tool to learn more about ATTR, RNAi therapeutics, findings from the HELIOS‑B study in ATTR‑CM, findings from the HELIOS‑A study in hATTR‑PN, and Alnylam’s commitment to ATTR. HELIOS‑B data include outcomes on survival, functional capacity, quality of life, CV events, exploratory measures of cardiac biomarkers, structure and function, post hoc extracardiac analyses, and safety. HELIOS‑A data include outcomes on neuropathy impairment, quality of life, gait speed, nutritional status, disability, and safety. Navigate using the forward and backward controls. For optimal viewing, enter full-screen mode.
Overview of the HELIOS‑B Study
This expert video with Ronald Witteles, MD, summarizes the findings from the HELIOS‑B study of vutrisiran in ATTR‑CM
You are now leaving this site and being directed to a third-party website that is not maintained by Alnylam. Alnylam does not endorse and is not responsible for content or maintenance of third-party websites.
Navigating to another Alnylam website
You are now leaving this site and being directed to another Alnylam website.
Share this resource
OR
Search for educational content on Disease & Therapeutic Areas and Alnylam Therapies
Use the "Search" feature to discover Disease & Therapeutic Area educational content based on key terms
More than one search term is recommended to yield the most relevant results
By searching, you confirm that your query is unsolicited
We’re sorry, no results were found for your search: Hypertnghy
For further information regarding your request, please connect with us
Intended for US healthcare professionals. This site is intended to provide balanced, evidence-based information to support scientific exchange. It is not intended to provide medical advice or recommendations for clinical practice.
Information about investigational therapeutics or investigational uses of approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.
Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.
Are you a healthcare professional practicing in the United States?
